MedTrace Logo

Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma

NCT00002985 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-02-04

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether doxorubicin is more effective than daunorubicin for AIDS-related Kaposi's sarcoma.

PURPOSE: Randomized double-blinded phase III trial to determine if doxorubicin is more effective than daunorubicin in treating patients who have AIDS-related Kaposi's sarcoma.

Conditions

  • Sarcoma

Interventions

DRUG

daunorubicin hydrochloride

DRUG

pegylated liposomal doxorubicin hydrochloride

Sponsors & Collaborators

  • Roswell Park Cancer Institute

    lead OTHER

Principal Investigators

  • Lawrence P. Leichman, MD · Albany Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-11-30
Primary Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002985 on ClinicalTrials.gov